Pancreatic Cancer Research

ResearcherHumboldt-Universität zu BerlinNo recent work listed

Jana Käthe Striefler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0612-3023; OpenAlex author ID A5057927443. Sources: OpenAlex.

Their work

Papers
21 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
39
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: 2 papers

Papers 21

  1. Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
  2. Dual Targeting of the EGFR/HER2 Pathway in Combination with Systemic Chemotherapy in Refractory Pancreatic Cancer-The CONKO-008 Phase I Investigation. Co-author DOI 10.3390/jcm11164905↗
  3. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial. Co-author DOI 10.1016/j.ebiom.2021.103327↗
  4. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma -… Co-author DOI 10.1016/j.ejca.2021.03.036↗
  5. Mucin-1 Protein Is a Prognostic Marker for Pancreatic Ductal Adenocarcinoma: Results From the CONKO-001 Study. Co-author DOI 10.3389/fonc.2021.670396↗
  6. CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic can… Co-author DOI 10.1016/j.ejca.2020.06.032↗
  7. TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO… Co-author DOI 10.1158/1078-0432.ccr-19-3034↗
  8. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospecti… Co-author DOI 10.1016/j.ejca.2018.06.001↗
  9. Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-018-0093-y↗
  10. Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejca.2017.06.016↗
  11. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Ra… Co-author DOI 10.1200/jco.2017.72.6463↗
  12. P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Co-author DOI 10.1016/j.prp.2016.06.001↗
  13. Second-Line Treatment in Pancreatic Cancer Patients: Who Profits?--Results From the CONKO Study Group. Co-author DOI 10.1097/mpa.0000000000000533↗
  14. Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer. Co-author DOI 10.1002/jso.23951↗
  15. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treat… Co-author DOI 10.1016/j.ejca.2015.05.005↗
  16. α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study. Co-author DOI 10.1038/bjc.2014.495↗
  17. SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study. Co-author DOI 10.1093/annonc/mdu084↗
  18. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.1097/mpa.0000000000000077↗
  19. Intensity-modulated and image-guided radiotherapy in patients with locally advanced inoperable pancreatic cancer after preradiation chemotherapy. Co-author DOI 10.1155/2014/452089↗
  20. Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study. First author DOI 10.1002/jso.23409↗
  21. High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer. Co-author DOI 10.1111/j.1365-2559.2012.04225.x↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marianne Sinn · 20 shared papers, 2013–2022 · strength 1.41
  2. Uwe Pelzer · 19 shared papers, 2013–2022 · strength 1.37
  3. Hanno B. Riess · 20 shared papers, 2012–2022 · strength 1.33
  4. Helmut Oettle · 15 shared papers, 2013–2022 · strength 1.09
  5. Marcus Bahra · 17 shared papers, 2012–2022 · strength 1.06
  6. Philipp Lohneis · 9 shared papers, 2014–2021 · strength 0.61
  7. Bruno Valentin Sinn · 11 shared papers, 2012–2021 · strength 0.60
  8. Carsten Denkert · 11 shared papers, 2012–2021 · strength 0.60
  9. Jens Stieler · 9 shared papers, 2013–2022 · strength 0.48
  10. Anja Jühling · 4 shared papers, 2016–2018 · strength 0.26
  11. Annika Kurreck · 2 shared papers, 2021 · strength 0.24
  12. Dominik Paul Modest · 2 shared papers, 2021 · strength 0.24
  13. Fritz Klein · 3 shared papers, 2015–2018 · strength 0.20
  14. Frédérik Damm · 2 shared papers, 2020–2021 · strength 0.19
  15. Frederick Klauschen · 3 shared papers, 2012–2020 · strength 0.15
  16. Pirus Ghadjar · 1 shared paper, 2022 · strength 0.14
  17. Thomas Malinka · 1 shared paper, 2022 · strength 0.14
  18. Christopher Neumann · 1 shared paper, 2022 · strength 0.14
  19. Michael B. Ghadimi · 2 shared papers, 2017–2020 · strength 0.14
  20. Stephan Krüger · 1 shared paper, 2021 · strength 0.12
  21. Sven‐Thorsten Liffers · 1 shared paper, 2022 · strength 0.10
  22. Xin Zhang · 1 shared paper, 2022 · strength 0.10
  23. Rui Fang · 1 shared paper, 2022 · strength 0.10
  24. Phyllis F. Cheung · 1 shared paper, 2022 · strength 0.10
  25. Erik H.J.G. Aarntzen · 1 shared paper, 2022 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.